Femtech investment remains active in 2026 as women's health attracts greater attention from healthcare investors, employers, payers, and life-sciences companies. Dealroom reports that femtech startups raised $724 million in VC funding in 2025, with another $239 million raised in the first half of 2026. Across the broader women's health market, Silicon Valley Bank reports that $2 billion in VC was invested across the U.S. and Europe in 2025, with funding and deal volume projected to rebound in 2026.
For GTM teams tracking healthcare growth markets, femtech now extends well beyond period-tracking apps. The sector includes virtual care, fertility technologies, diagnostics, reproductive therapeutics, maternal health, menopause care, and clinical automation. Related Landbase research on fast-growing digital health companies and healthtech companies provides additional context for the broader healthcare technology market.
Key Takeaways
- Menopause and midlife care are attracting major capital - Midi Health reached a $1 billion valuation following its 2026 Series D
- Maternal care is scaling through payers and employers - Pomelo Care reached a $1.7 billion valuation while expanding beyond maternity
- Consumer scale remains important - Flo Health reported nearly 70 million monthly active users when it announced its 2024 Series C
- Clinical innovation is broadening femtech - ReproNovo, Gameto, Conceivable Life Sciences, and Rejoni illustrate growth beyond software-only models
- Growth signals vary by company type - Patient volume, covered lives, clinical trials, regulatory milestones, funding, and commercial expansion can all indicate momentum
Why Femtech Investment Is Accelerating
Women's health has historically received less research and investment attention than its population and economic impact would suggest. That gap has created opportunities across fertility, menopause, maternal health, reproductive medicine, diagnostics, and chronic conditions affecting women.
Industry research cited by Jones Day projects substantial long-term growth in femtech as healthcare delivery, biotechnology, digital platforms, and medical devices converge around women's health needs.
Several forces are supporting this expansion:
- Demographic demand - More patients are seeking specialized menopause, fertility, and reproductive healthcare
- Employer and payer adoption - Women's and family health programs increasingly operate through benefits and health-plan channels
- Clinical technology - AI, robotics, diagnostics, telehealth, and biotechnology are expanding available care models
- Commercial validation - Funding is increasingly accompanied by measurable patient growth, clinical evidence, geographic expansion, or commercialization progress
For RevOps and sales organizations, these developments can provide useful inputs for account research and market-specific list building.
1. Midi Health
Focus: Virtual midlife and women's healthcare
CEO: Joanna Strober, Co-founder
Recent Funding: $100M Series D, February 2026
Valuation: More than $1B
Midi Health began with perimenopause and menopause care and has expanded toward a broader women's healthcare platform. Its $100 million Series D valued the company at more than $1 billion in February 2026.
Key Metrics
- Patient scale - More than 25,000 patients per week by early 2026
- Insurance reach - Services available to more than 45 million women
- Expansion - Growing beyond menopause into broader midlife and longevity care
Why It Made the List
Midi combines rapid patient growth with nationwide insurance-backed care and significant growth capital. Its expansion into additional areas of women's health also increases its addressable market beyond menopause alone.
2. Pomelo Care
Focus: Women's, maternal, and children's healthcare
CEO: Marta Bralic Kerns, Founder
Recent Funding: $92M Series C, January 2026
Valuation: $1.7B
Pomelo Care provides virtual clinical care spanning reproductive health, pregnancy, pediatrics, hormonal health, perimenopause, and menopause. Its $92 million Series C valued the company at $1.7 billion.
Key Metrics
- U.S. birth reach - Supports nearly 7% of U.S. births
- Clinical evidence - Reports measurable improvements in maternal and infant outcomes
- Expansion - Moving beyond maternity into longitudinal women's and children's care
Why It Made the List
Pomelo combines rapid financing with health-plan and employer distribution and published outcomes data. Its expansion beyond pregnancy creates room for a broader longitudinal care model.
3. Maven Clinic
Focus: Women's and family health benefits
CEO: Kate Ryder, Founder
Recent Funding: $125M Series F, October 2024
Valuation: $1.7B
Maven Clinic provides fertility, family-building, maternity, parenting, menopause, and related healthcare programs through employers and health plans. Its Series F raised $125 million at a $1.7 billion valuation.
Key Metrics
- Provider network - More than 1,000 specialized providers
- Distribution - Employer and health-plan model
- Care breadth - Fertility through menopause and family health
Why It Made the List
Maven remains one of the most scaled women's and family health platforms. Its broad care model and established enterprise distribution distinguish it from companies concentrated on a single women's health category.
4. Flo Health
Focus: Digital women's health and cycle tracking
CEO: Dmitry Gurski, Co-founder
Recent Funding: More than $200M Series C, July 2024
Valuation: More than $1B
Flo Health became the first purely digital consumer women's health app to reach unicorn status following its General Atlantic investment. At the time of the round, Flo reported nearly 70 million monthly active users and close to five million paid subscribers.
Key Metrics
- Monthly active users - Nearly 70M at the 2024 financing
- Paid subscribers - Close to 5M
- Coverage - Menstruation, conception, pregnancy, and menopause
Why It Made the List
Flo demonstrates consumer adoption at a scale few women's health platforms have reached. Its subscription model and global reach provide a different growth profile from employer-backed or clinical-care platforms.
5. LetsGetChecked
Focus: At-home diagnostics and virtual healthcare
CEO: Peter Foley, Founder
Recent Funding: $165M Series F, January 2025
LetsGetChecked is a broader diagnostics company rather than a dedicated femtech platform, but women's health remains an important part of its offering. Its testing portfolio includes fertility, sexual health, hormone, HPV, thyroid, and other at-home diagnostic services.
Key Metrics
- Series F - $165M in January 2025
- Total funding - Approximately $448M
- Model - Consumer diagnostics alongside employer, payer, and healthcare partnerships
Why It Made the List
LetsGetChecked illustrates how women's health increasingly overlaps with the broader diagnostics market. Its existing testing infrastructure and healthcare partnerships create distribution opportunities across reproductive and preventive care.
6. ReproNovo
Focus: Reproductive medicine therapeutics
CEO: Jean Marie Duvall, Co-founder
Recent Funding: $65M Series A, May 2025
ReproNovo develops therapeutics for reproductive medicine and women's health. Its pipeline includes RPN-001 for male infertility and RPN-002 for adenomyosis and assisted reproductive technology applications.
Key Metrics
- Clinical stage - Multiple Phase 2 programs
- Series A - $65M
- Investors - Jeito Capital, AXA IM Alts, M Ventures, Ysios Capital, and ALSA Ventures
Why It Made the List
ReproNovo represents the therapeutics side of the sector, where clinical development can be a more meaningful growth indicator than user or revenue growth. Its financing is supporting multiple mid-stage clinical programs.
7. Gameto
Focus: Cell-based reproductive medicine
CEO: Dina Radenkovic, Co-founder
2024-2025 Funding: $33M Series B + $44M Series C
Gameto develops reproductive technologies using engineered ovarian support cells. Its lead program, Fertilo, is designed to support egg maturation for IVF and egg freezing while reducing dependence on prolonged hormonal stimulation.
Key Metrics
- Series C - $44M announced in August 2025
- Clinical progress - Fertilo has entered a Phase 3 clinical program
- Pipeline - Fertility, menopause, and ovarian-health applications
Why It Made the List
Gameto combines substantial recent financing with advanced clinical development. Progress into Phase 3 gives the company a different growth profile from earlier-stage fertility startups and moves its lead technology closer to potential commercialization.
8. Diana Health
Focus: Hospital-partnered women's healthcare
CEO: Kate Condliffe, Co-founder
Recent Funding: $55M Series C, September 2025
Diana Health works with hospitals to develop integrated women's health programs combining certified nurse-midwives, OB-GYNs, mental health professionals, wellness services, and supporting technology.
Key Metrics
- Series C - $55M led by HealthQuest Capital
- Expansion - Nine locations across Tennessee, Florida, and Texas at the funding announcement
- Model - Women's health practices built in partnership with existing health systems
Why It Made the List
Diana Health follows a different expansion path from virtual-only platforms. Its hospital partnership model uses established health systems as a foundation for geographic and clinical growth.
9. Conceivable Life Sciences
Focus: Automated IVF laboratories
CEO: Alan Murray
Recent Funding: $50M Series A, September 2025
Conceivable Life Sciences develops AI-powered robotics for IVF laboratories. Its AURA platform is designed to automate traditionally manual embryology processes and improve consistency and scalability within fertility treatment.
Key Metrics
- Series A - $50M
- Technology - AI and robotics for IVF laboratories
- Commercial focus - Scaling automated fertility-laboratory infrastructure
Why It Made the List
IVF laboratories depend on highly specialized staff and complex manual workflows. Conceivable targets that operational bottleneck by applying robotics and automation to laboratory processes, giving it a distinct position within fertility technology.
10. Rejoni
Focus: Uterine-health biomaterials
CEO: John Nealon
Recent Funding: $25M financing, June 2026
Rejoni develops biomaterial technologies for uterine health. Its lead product, the Juveena Hydrogel System, is designed to support endometrial healing and help prevent intrauterine adhesions following certain intrauterine procedures. The product remains subject to regulatory approval.
Key Metrics
- 2026 financing - $25M
- Regulatory progress - Juveena continued advancing through the FDA review process
- Leadership - John Nealon became CEO in 2026
Why It Made the List
Rejoni combines recent financing with regulatory progress toward potential commercialization. That combination makes clinical and regulatory milestones more relevant to its growth trajectory than traditional software metrics such as monthly users.
How Landbase Supports Femtech Market Mapping
Femtech does not fit neatly into a single conventional industry category. Relevant companies may be classified as telehealth providers, biotechnology startups, diagnostics companies, medical-device manufacturers, fertility businesses, or healthcare software companies.
Landbase CLI provides programmatic access to Landbase data and agent workflows from the terminal and environments such as Claude Code and Codex. This can help GTM engineers and RevOps teams define specialized healthcare audiences without depending entirely on broad industry classifications.
Building More Precise Femtech Audiences
Natural-language audience creation allows teams to combine characteristics that may otherwise require several separate filters. A search could focus on women's health companies at particular funding stages, reproductive-health businesses in specific geographies, or healthcare companies showing expansion activity.
Landbase's guidance on prompting like an operator provides a framework for translating those criteria into more structured audience requests.
Combining Company Signals
Financing alone does not indicate that every company is entering the same buying cycle. Relevant signals can include:
- New funding
- Hiring acceleration
- Executive appointments
- Geographic expansion
- Technology adoption
- New commercial programs
Landbase workflows can stack buying signals rather than relying on a single event.
Matching and Enriching Existing Lists
Teams that already maintain women's health, fertility, or digital-health account lists can use file upload, matching, and enrichment to connect existing records with additional company or contact data.
This approach can help maintain a market map as companies change funding stages, expand teams, or move from clinical development toward commercialization.
Structured Data for Technical GTM Workflows
Landbase CLI can return structured datasets for downstream use in scripts, analysis, CRM processes, and agent-assisted workflows. For technical revenue teams working across specialized healthcare markets, this provides a path from market definition to account data without rebuilding the research process for each campaign.
Frequently Asked Questions
What defines a fast-growing femtech company?
A fast-growing femtech company typically shows several forms of momentum rather than funding alone. Relevant indicators include large or closely spaced financing rounds, revenue or patient growth, health-plan or employer distribution, clinical milestones, regulatory progress, geographic expansion, and new commercial infrastructure. The companies on this list were selected because they show multiple recent indicators across 2024-2026.
How does femtech contribute to addressing health disparities for women?
Femtech focuses on health needs that solely, disproportionately, or differently affect women, including menopause, reproductive health, pregnancy, fertility, and gynecological conditions. New care models can improve access to specialists, while diagnostics, therapeutics, and clinical technologies can address areas that historically received less research or investment attention.
What are the typical funding stages for a femtech startup?
Femtech companies follow many of the same financing stages as other venture-backed healthcare businesses, from seed and Series A through later-stage rounds. Capital requirements vary considerably by model. A virtual-care platform may scale through software, clinicians, and payer contracts, while biotechnology or medical-device companies may require larger investments for clinical trials, regulatory work, manufacturing, and commercialization.
Who are some major investors in the femtech space?
Recent rounds include participation from investors such as General Atlantic in Flo Health, Stripes in Pomelo Care, Goodwater Capital in Midi Health, HealthQuest Capital in Diana Health, and Advance Venture Partners in Conceivable Life Sciences. Corporate and healthcare investors are also active, including Optum Ventures and M Ventures, Merck's corporate venture arm.
How can Landbase help GTM teams identify high-growth femtech companies?
Landbase CLI allows GTM teams to define specialized audiences using natural-language criteria and combine those criteria with company and buying signals. Rather than using funding as the only indicator, teams can incorporate hiring, executive changes, market expansion, and other events, then use matching and enrichment to prepare account and contact data for downstream workflows.
.png)
.png)
